ascopubs.org

Economic analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) use based on a risk model for neutropenic complications in breast cancer patients receiving ...

Providing practitioner-specific outcomes is associated with higher patient satisfaction with information about prostate cancer treatment This is an ASCO Meeting Abstract from the 2006 ASCO Annual ...
MedPage Today

Steroids and G-CSF Boost 90-Day Survival in Severe Alcoholic Hepatitis

WASHINGTON -- Research presented here at the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases included a better combination for severe alcoholic hepatitis, ...
Center for Biosimilars

FDA Approves Filkri, Accord BioPharma’s Short-Acting Filgrastim Biosimilar for Neutropenia

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.
ascopubs.org

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database.

Assessment of weight change and BMI as prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in a Polish female cohort. A phase I/II study evaluating the safety and ...
Labroots

Study Explores Role of Cannabinoid Receptor Type 2 Activity in Granulocyte Colony-Stimulating Factor (G-CSF) Treatment for Traumatic Brain Injury (TBI)

A study published in the Journal of Cannabis Research examined the effect of granulocyte colony-stimulating factor (G-CSF) on brain recovery following traumatic brain injury (TBI). The findings showed ...